Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Abstract
We sought to validate levels of CD8+ tumor-infiltrating cells (TIC) expressing PD-1 but not TIM-3 and LAG-3 (IF biomarker; Pignon and colleagues, 2019) and to investigate human endogenous retroviruses (hERV) as predictors of response to anti–PD-1 in a randomized trial of nivolumab (nivo) versus everolimus (evero) in patients with metastatic clear cell renal cell carcinoma (mccRCC; CheckMate-025).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3084
Entities
People
- Abdallah Flaifel
- Arlene Sharpe
- Catherine J Wu
- David A Braun
- David F McDermott
- F Stephen Hodi
- Gordon J. Freeman
- Jean-christophe Pignon
- Maura A. Sticco-ivins
- Megan Wind-Rotolo
- Michael B Atkins
- Miriam Ficial
- Miriam Sant’angelo
- Opeyemi Jegede
- Paul J. Catalano
- Robert Motzer
- Sabina Signoretti
- Sachet A Shukla
- Toni K Choueiri
- Yue Hou
Organizations
- Brigham and Women's Hospital
- Dana Farber Harvard Cancer Center
- Dana–Farber Cancer Institute
- Dermatology Foundation
- Harvard Medical School
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- United States Department of Defense